

Ozop Surgical Corp.

13:00 30 Mar 2019

Ozop Surgical moves to crack code of minimally invasive spine surgery

- The purchase of Spinus LLC for \$782,289 gave the company the rights to a portfolio of intellectual property as well as an FDA-approved line of spinal products
- Ozop went public in April 2018 through a reverse merger and late last year was promoted to the OTCQB, the second tier of the OTC Markets
- Serving as CEO is Michael Chermak, who assumed that role in September 2016 and owns an 18% stake in the company as of November 2018
- A recent addition to the executive team is Thomas McLeer, whose prior work includes serving as an executive at LinkSpine
- Other areas of interest for Ozop are neurological and pain-management procedures

What does Ozop Surgical do?

Ozop Surgical Corp (OTCMKTS:OZSC) is working to realize the promise of minimally invasive spinal surgery for the millions of people suffering from severe back pain.

Over the past 20 years, minimally invasive surgery has transformed medical procedures ranging from gall bladder and appendix removal to valve replacement and bypass surgery to orthopedics procedures involving knees, shoulders and hips. For patients, the benefits include lower costs, fewer complications, faster recovery and less pain.

Spinal surgery has been a laggard, according to Ozop, because most procedures require the placement of relatively large objects such as screws or plates.

Other areas of interest for Ozop are neurological and pain-management procedures. The company also invents, designs, develops, manufactures and distributes endoscopic instruments, surgical implants, instrumentation and related technologies

Ozop's key assets

A key area of focus for the West Palm Beach, Florida, company is development of balloon lumbar interbody fusion (BLIF) technology for minimally invasive spine surgery. ("BLIF" is pronounced "bee" and then "lif, which rhymes with "cliff.")


Medical-quality balloons are routinely used for opening clogged arteries, repairing broken bones and other procedures. The advantage of a balloon is that it can be inserted into a small incision and then inflated to the proper size.

With BLIF, according to Ozop, a needle or wire is used to get to a damaged disc. Once imaging confirms placement, a small tube is placed over the needle or wire. Through this portal, an endoscope can be used to view the disc and damaged tissue is removed. (The tube protects surrounding muscle and tissue are protected from damage by the tube.)

Price: US\$0.41

Market Cap: US\$11.98M

1 Year Share Price Graph



October 2018 February 2019 April 2019

Share Information

Code: OZSC

Listing: OTCMKTS

52 week	High	Low
	\$2.10	\$0.05

Sector: Health Care, Equipment & Services

Website: ozopsurgical.com

Company Synopsis:

Ozop Surgical Corp. invents, designs, develops, manufactures and globally distributes innovative endoscopic instruments, surgical implants, instrumentation, devices and related technologies, focused on spine, neurological and pain management procedures and specialties.

Author:

Proactive Investors Ltd

+44 (0)207 989 0813

action@proactiveinvestors.com

Once the damaged material has been removed, the disc is measured and a balloon is inserted and filled with a hardening polymer. A surgeon can then fill in the area around the implant with bone graft to help promote fusion of the spine.

Expected milestones for Ozop's BLIF technology include establishing an experienced team of surgeons and industry experts to hone the technique and then complete tests for submission to the Food and Drug Administration.

In addition, the company has begun development of an enhanced expandable anterior lumbar interbody fusion (ALIF) implant, with initial designs and prototypes completed. This product, according to Ozop, is easier to insert and use than competing products.

The company expects to complete design and testing in the first half of 2019 and anticipates FDA approval in the second half.

Other products in the pipeline include visualization tools for minimally invasive surgery including light filtration and 3D technology.

Inflection points

Ozop started to gain momentum in February 2018, when its purchase of Spinus LLC for \$782,289 gave the company the rights to what it says is a rich intellectual property portfolio as well as an FDA-approved line of spinal products.

Another big step came when the company went public in April 2018 through a reverse merger. The partner in the deal was a publicly traded entity that rented bicycles, Segways and related equipment in Lithuania. Last December, just several months after the reverse merger, Ozop was promoted to the OTCQB exchange, the second tier of the OTC Markets.

Serving as CEO is Michael Chermak, who assumed that role in September 2016 and owns an 18% stake in the company. He sold a company he founded, Healthdemographics Inc, to Medirisk, a Dutch company, in 1997. He continues to serve as managing director of Makena Investment Advisers LLC and as president of MD Capital Advisers Inc.

Ozop's biggest shareholder, with a 37% stake, is Eric Siu, who serves as the company's director of endoscopic program development. Siu, according to Ozop, has spent more than a decade creating intellectual property and developing minimally invasive endoscopic products.

A recent addition to the executive team is Thomas McLeer, the company's chief operating officer since October. His prior work includes serving as vice president of sales and marketing at Rockaway, New Jersey-based LinkSpine.

Contact Dennis Fitzgerald at dennis@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors

may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.